QIAGEN to develop new companion diagnostic for compound in clinical trials for blood cancers
Lilly will co-develop companion diagnostic
08-Sep-2011 -
QIAGEN announced that it has entered into a partnership with Eli Lilly and Company for the development, manufacturing and commercialization of a molecular companion diagnostic for an early stage investigational compound currently being developed by Lilly. Financial terms of the agreement were ...
biomarkers
blood cancer
diagnostics
+3